7 citations
,
January 2021 in “Dermatology and therapy” Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
June 2026 in “Saudi Medical Horizons Journal” JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
August 2022 in “Precision Clinical Medicine” JAM-A helps hair regrowth in alopecia areata by protecting VCAN in skin cells.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
7 citations
,
March 2022 in “The FASEB journal” Adult mice with CBS deficiency show minimal health issues and normal lifespan despite high homocysteine levels.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
3 citations
,
April 2022 in “Cutis” CCCA is a common, scarring hair loss in Black women that needs early detection.
December 2025 in “Cureus” Localized dystrophic epidermolysis bullosa (DEB) can lead to scarring alopecia, highlighting the need to recognize and address this complication.
April 2018 in “Journal of Investigative Dermatology” Higher levels of nidogen1 and type IV collagen are found in basal cell carcinoma compared to normal skin.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.